192 related articles for article (PubMed ID: 32243243)
1. 5α-Reductase Inhibitors and Risk of Prostate Cancer Death.
Bonde Miranda T; Garmo H; Stattin P; Robinson D
J Urol; 2020 Oct; 204(4):714-719. PubMed ID: 32243243
[TBL] [Abstract][Full Text] [Related]
2. Impact of 5α-Reductase Inhibitors on Disease Reclassification among Men on Active Surveillance for Localized Prostate Cancer with Favorable Features.
Dai C; Ganesan V; Zabell J; Nyame YA; Almassi N; Greene DJ; Hettel D; Reichard C; Haywood SC; Arora H; Zampini A; Crane A; Li J; Elshafei A; Magi-Galluzzi C; Stein RJ; Fareed K; Gong M; Jones JS; Klein EA; Stephenson AJ
J Urol; 2018 Feb; 199(2):445-452. PubMed ID: 28789947
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Prostate Cancer Screening by 5α-Reductase Inhibitor Use.
Murtola TJ; Virkku A; Talala K; Stenman UH; Taari K; Tammela TLJ; Auvinen A
J Urol; 2017 Aug; 198(2):305-309. PubMed ID: 28216328
[TBL] [Abstract][Full Text] [Related]
4. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
[TBL] [Abstract][Full Text] [Related]
5. Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS.
Kearns JT; Faino AV; Schenk JM; Newcomb LF; Brooks JD; Carroll PR; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner A; Zheng Y; Lin DW
J Urol; 2019 Jan; 201(1):106-111. PubMed ID: 30076904
[TBL] [Abstract][Full Text] [Related]
6. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer.
Preston MA; Wilson KM; Markt SC; Ge R; Morash C; Stampfer MJ; Loda M; Giovannucci E; Mucci LA; Olumi AF
JAMA Intern Med; 2014 Aug; 174(8):1301-7. PubMed ID: 24887392
[TBL] [Abstract][Full Text] [Related]
7. High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers.
Murtola TJ; Kujala PM; Tammela TL
Prostate; 2013 Jun; 73(9):923-31. PubMed ID: 23334943
[TBL] [Abstract][Full Text] [Related]
8. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
9. Use of 5α-reductase inhibitors for benign prostate hypertrophy and risk of high grade prostate cancer: a French population-based study.
Scailteux LM; Rioux-Leclercq N; Vincendeau S; Balusson F; Nowak E; Oger E;
BJU Int; 2019 Feb; 123(2):293-299. PubMed ID: 30025199
[TBL] [Abstract][Full Text] [Related]
10. 5-Alpha reductase inhibitor use and prostate cancer survival in the Finnish Prostate Cancer Screening Trial.
Murtola TJ; Karppa EK; Taari K; Talala K; Tammela TL; Auvinen A
Int J Cancer; 2016 Jun; 138(12):2820-8. PubMed ID: 26804670
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors.
Fradet V; Toren P; Nguile-Makao M; Lodde M; Lévesque J; Léger C; Caron A; Bergeron A; Ben-Zvi T; Lacombe L; Pouliot F; Tiguert R; Dujardin T; Fradet Y
BJU Int; 2018 Mar; 121(3):399-404. PubMed ID: 28972698
[TBL] [Abstract][Full Text] [Related]
12. Risk of Prostate Cancer in Men Treated With 5α-Reductase Inhibitors-A Large Population-Based Prospective Study.
Wallerstedt A; Strom P; Gronberg H; Nordstrom T; Eklund M
J Natl Cancer Inst; 2018 Nov; 110(11):1216-1221. PubMed ID: 29548030
[TBL] [Abstract][Full Text] [Related]
13. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
Azoulay L; Eberg M; Benayoun S; Pollak M
JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
[TBL] [Abstract][Full Text] [Related]
14. Bladder Cancer Survival of Men Receiving 5α-Reductase Inhibitors.
Mäkelä VJ; Kotsar A; Tammela TLJ; Murtola TJ
J Urol; 2018 Oct; 200(4):743-748. PubMed ID: 29730200
[TBL] [Abstract][Full Text] [Related]
15. Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial.
Fowke JH; Howard L; Andriole GL; Freedland SJ
Eur Urol; 2014 Dec; 66(6):1133-8. PubMed ID: 24568894
[TBL] [Abstract][Full Text] [Related]
16. Pre-radiotherapy PSA progression is a negative prognostic factor in prostate cancer patients using 5‑alpha-reductase inhibitors.
Taussky D; Piotte J; Zorn KC; Zanaty M; Krishnan V; Lambert C; Bahary JP; Beauchemin MC; Barkati M; Ménard C; Delouya G
Strahlenther Onkol; 2018 Jan; 194(1):17-22. PubMed ID: 28695317
[TBL] [Abstract][Full Text] [Related]
17. Association between 5α-reductase inhibitors therapy and incidence, cancer-specific mortality, and progression of prostate cancer: evidence from a meta-analysis.
Luo LM; Yang RD; Wang JM; Zhao SK; Liu YZ; Zhu ZG; Xiang Q; Zhao ZG
Asian J Androl; 2020; 22(5):532-538. PubMed ID: 31710001
[TBL] [Abstract][Full Text] [Related]
18. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
[TBL] [Abstract][Full Text] [Related]
19. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
[TBL] [Abstract][Full Text] [Related]
20. Levels of 5alpha-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer.
Thomas LN; Douglas RC; Lazier CB; Gupta R; Norman RW; Murphy PR; Rittmaster RS; Too CK
J Urol; 2008 Jan; 179(1):147-51. PubMed ID: 17997435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
